HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma by unknown
Kren et al. Diagnostic Pathology 2012, 7:58
http://www.diagnosticpathology.org/content/7/1/58RESEARCH Open AccessHLA-G and HLA-E specific mRNAs connote
opposite prognostic significance in renal
cell carcinoma
Leos Kren1*, Ivo Valkovsky2, Jan Dolezel3, Ivo Capak3, Dalibor Pacik4, Alexandr Poprach5, Radek Lakomy5,
Martina Redova5,6, Pavel Fabian7, Zdenka Krenova8 and Ondrej Slaby5,6Abstract
Background: Renal cell carcinoma (RCC) is characterized by its resistance to radiotherapy and/or chemotherapy. On
the other hand, it is an immunogenic tumor - it is able to stimulate antitumor responses. A prognostic significance
of HLA-G expression by neoplastic cells in RCC is not well characterized; significance HLA-E expression in RCC is not
characterized at all.
Methods: In our study, we evaluated the expression of HLA-G and HLA-E specific mRNA transcripts produced by
neoplastic cells in 38 cases of RCC and in 10 samples of normal kidney parenchyma. The results were statistically
correlated with various clinico-pathological parameters.
Results: We confirmed that HLA-G is downregulated in normal kidney tissue; if it is up-regulated in RCC, then it is
connected to worse prognosis. On the other hand, HLA-E mRNA transcripts were present in both normal kidney
tissue and RCC and their increasing concentrations counterintuitively carried better prognosis, more favorable pT
stage and lower nuclear Fuhrmann’s grade.
Conclusion: Considering the fact that there is known aberrant activation of HLA-G and HLA-E expression by
interferons, identification of HLA-G and HLA-E status could contribute to better selection of RCC patients who could
possibly benefit from more tailored neoadjuvant biological/immunological therapy. Thus, these molecules could
represent useful prognostic biomarkers in RCC, and the expression of both these molecules in RCC deserves further
study.
The virtual: Slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7383071387016614Introduction
Nonclassical human leukocyte molecules G and E (HLA-G
and HLA-E) were originally thought to be specifically
expressed only on extravillous trophoblast - fetal tissue in
contact with maternal cells which lacks MHC class I anti-
gens. The initial described function of these molecules was
the protection of fetal semiallogeneic graft from maternal
allorecognition (‘pregnancy sentinels’) [1,2].
Currently, it is known that HLA-G and HLA-E exert
multiple immunoregulatory functions. HLA-G is well* Correspondence: lkren@fnbrno.cz
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reproduction in any medium, provided the orknown for its immuno-tolerogenic properties utilized by
neoplastic cells in many malignancies where its expres-
sion may represent one of the various mechanisms used
by tumor cells to thwart the immune response.
Immuno-modulatory molecule HLA-E function is
more complex: it can act as both immuno-tolerogenic
and immuno-activating molecule, depending on the type
of NK cell receptor it is associated with. Furthermore,
HLA-E can associate with ‘non-canonical’ peptides and
utilize CD8 T-cell receptor-mediated recognition.
Renal cell carcinoma (RCC) has several subtypes, usually
identifiable by H+E stain; in some subtypes, ancillary
techniques are beneficial for accurate diagnosis [3]. Inter-
estingly, some RCC express neuroendocrine markers,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.


















* Recurrence-free survival = 11.5 (5-36) months.
** Follow-up = 50 (41-62) months.
Medians and 25th and 75th percentiles in parentheses.
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RCC is characterized by its resistance to radiotherapy and/
or chemotherapy; on the other hand, it is an immunogenic
tumor - it is able to stimulate antitumor responses. A
prognostic significance of the expression of HLA-G by
neoplastic cells in RCC is not well characterized, and the
significance of the expression of HLA-E in RCC is not
characterized at all. Therefore, in our study, we evaluated
the expression of HLA-G and HLA-E specific mRNA




Thirty-eight patients (24 men, 14 women) diagnosed
with renal cell carcinoma of a clear type at the Masaryk
Memorial Cancer Institute (Brno, Czech Republic) be-
tween 2003 and 2009 were included in this study. All
cases/tissues represented consecutive cases and primary
diagnoses. The examination of human tissues was
approved by the Hospital´s Ethical Committee. These
examinations were carried out in accordance with the
ethical standards laid down in an appropriate version of
the 1964 Declaration of Helsinki. Patients' ages ranged
from 41 to 89 years, with a median of 68 years. Histo-
logical diagnoses were established according to the
guidelines of the latest WHO classification. Cases were
selected according to tissue availability and were not
stratified for any known preoperative or pathological
prognostic factor. Clinical follow-up data in the form of
annually assessed survival time was available for all
patients. No patient received any neoadjuvant therapy
including biological therapy/immunotherapy. The me-
dian follow-up time for all cases was 40 months and ran-
ged from 3 to 105 months. Clinical characteristics of the
patients are summarized in Table 1.
Tissue sample preparation and RNA purification
Under the supervision of an experienced pathologist, 48
tissue samples were collected (before start of any treat-
ment) from surgically resected tissues - 38 samples from
primary tumors and 10 from adjacent non-tumoral renal
parenchyma. The inclusion criterion was at least 70% of
tumor cells in the sample (confirmed by frozen section
of the included tissue). All samples were immediately
stored in liquid nitrogen until RNA extraction. Samples
were homogenized with tissue homogenizer MM301
(Retch, Germany) in sterile conditions before total RNA
isolation. Total RNA isolation procedure was performed
using the RNeasy Mini Kit (Qiagen) according to manu-
facturer’s instructions Total RNA concentration and pur-
ity were controlled by UV spectrophotometry (A260:
A280> 2.0; A260:A230> 1.8) using Nanodrop ND-1000
(Thermo Scientific, USA).Reverse transcription and real-time qPCR
cDNA was obtained by reverse transcription (Thermocy-
cler Tgradient; Biometra). Reaction mixture containing
1ug of total RNA, random hexamers (Qiagen) and
RNAse-free water was incubated at 65°C for 5 min, then
cooled quickly on ice, and the following components
added to 20uL final volume: 5X Reaction Buffer, Ribo-
nuclease Inhibitor, dNTP mix, Revert AidTM MMuLV
H-Reverse Transcriptase (all from Fermentas) and
RNAse-free water. The mixture was incubated for 120
min at 42°C, and the reaction was stopped by heating
the mixture at 95°C for 5 min and chilled on ice. The
real-time PCR was performed using Applied Biosystems
7500 Sequence Detection System according to manufac-
turer’s recommendations. The PCR mixture, with a total
volume of 20 ul, included 4 ul of the reverse transcrip-
tion product, 10ul of 2X TaqMan Universal PCR Master
Mix, 1 ul of 20X Primers and probe mix of the TaqMan
Expression Assays for HLA-G (Hs00365950_g1) and
HLA-E (Hs03045171_m1) and 5ul of RNAse-free water.
Used primers amplify all of HLA-G splice variants
(spanning exons 5-6). The mixture was incubated in 96-
well optical plates at 50°C for 2 min, 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
The Ct data were determined with default threshold set-
tings. All reactions were run in duplicates, and average Ct
and standard deviation values were calculated.
Immunohistochemistry
Immunohistochemical analysis was performed by using
antibodies to HLA-G (isoform G1, clone MEM-G/1,
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/02, dilution 1:25, Exbio Prague). Dilution was done by
Dako REAL™ Antibody Diluent, DAKO. Formalin fixed
paraffin embedded 4 μm thick whole tissue sections
were cut. Tissue microarray technique was not used to
avoid its possible pitfalls [5]. Following deparaffinization
(pure xylen 3 × 5 min, 96% alcohol 3 × 5 min, rinsed by
distilled water), inactivation of endogenous peroxidase
(3%H2O2 in methanol for 10 min, rinsed by distilled
water) and antigen retrieval (citrate buffer of pH 6.0 at
98°C for 20 min, cooling for 20 min, PBS buffer
3 × 5 min) followed incubations with primary antibodies.
Incubations were performed in a wet chamber for 1 h at
room temperature (20°C) followed by PBS buffer
3 × 5 min. Streptavidin–biotin peroxidase detection sys-
tem was used based on manufacturer's instructions (En-
Vision + System, HRP Labeled Polymer anti Mouse,
DAKO) in a wet chamber for 45 min at room
temperature, washed by PBS buffer, and then visualized
using 3,3′ diaminobenzidine (DAB) as a substrate
(Sigma). Nuclei were counterstained by Gill's hematoxy-
line for 1 min followed by bluing in water for 2–3 min
for optimal results. Following dehydration in a series of
up-concentrated ethanol baths and clearing in xylene,
the specimens were mounted in Entelan™.Statistical analysis
Expression data were normalized according to the ex-
pression of the reference gene GAPDH (Assay No.
402869; Applied Biosystems). Statistical differences be-
tween clinico-pathological parameters and mRNA levels
were evaluated using the Mann–Whitney U-test between
two independent groups and Wilcoxon test between
paired groups and the Kruskal-Wallis test for 3 or more
groups. The cut-off value for the HLA-G specific mRNAs
expression was set to 75th percentile of HLA-G expres-
sion levels in RCC tissue. For the HLA-E specific mRNAs
expression, the cut-off was set to 25th percentile of
HLA-E expression levels in RCC tissue: owing to the
relatively limited number of patients in our study, we
used this strategy to select the closest quartile of ROC-Table 2 Expression levels of HLA-G and HLA-E in RCC tissue in
non-paired samples
RCC renal parenchyma p-va
n= 38 n=10










* Medians of expression level related to GAPDH with **25th and 75th percentiles.identified cut-offs and use them as final cut-off values to
be more illustrative for further independent studies.
The long-rank test was used to measure the differ-
ences in Kaplan–Meier curves. P-values lower than 0.05
were considered to be statistically significant. All calcula-
tions were performed with the software Statistica (Stat-
Soft Inc., version 6.0, Tulsa, OK, USA).Results
Expression levels of HLA-G and HLA-E in RCC tissue
in comparison to non-neoplastic renal parenchyma are
shown in Table 2. These results indicate that HLA-G
specific mRNA transcripts were not - except of one sam-
ple - detectable in normal renal parenchyma. On the
other hand, HLA-G specific mRNA transcripts were de-
tectable in tissues of RCC in 29 cases (out of 38, i.e.
76%) and that there was a correlation between the pres-
ence of HLA-G specific mRNA transcripts in RCC tissue
and normal renal parenchyma (p = 0.031 for paired sam-
ples, p = 0.006 for non-paired samples). HLA-E specific
mRNA transcripts, though, were detectable in both nor-
mal renal parenchyma and tissues of RCC in all samples
(Table 3), and there was no correlation between HLA-E
mRNA transcripts in RCC tissue and normal renal par-
enchyma (p = 0.82 for paired samples, p = 0.14 for non-
paired samples). Comparison of HLA-G expression
levels in RCC tissue and non-tumoral renal parenchyma
(p = 0.0058, Mann–Whitney test) is shown in Figure 1.
Comparison of HLA-E expression levels in RCC tissue
and non-tumoral renal parenchyma (p = 0.126, Mann–
Whitney test) is shown in Figure 2.
Relapse-free survival of RCC patients based on the
HLA-G expression (p = 0.0401, Log-rank test) is shown
in Figure 3. These results indicate that there is a negative
correlation between HLA-G expression and the length
of relapse-free survival.
Relapse-free survival of RCC patients based on the
HLA-E expression (Log-rank test) is shown in Figure 4.
These results indicate that there is a positive correlation
between levels of HLA-E specific mRNA transcripts and
the length of relapse-free survival.comparison to renal parenchyma
paired samples
lue RCC renal parenchyma p-value
n = 10 n=10










Table 3 Percentages of HLA-G and HLA-E in normal renal
parenchyma and RCC tissues
Normal kidney (n = 10) RCC (n = 38)
HLA-G positive 1 (10%) 29 (76%)
HLA-E positive 10 (100%) 38 (100%)
Figure 2 Comparison of HLA-E expression levels in RCC tissue
and non-tumoral renal parenchyma (p = 0.126, Mann–Whitney
test).
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and pT stage (p = 0.2649; Mann–Whitney test) and Fuhr-
mann’s grade (p = 0.1949, Mann–Whitney test).
HLA-E expression levels in RCC of different pT stage
(p = 0.041, Mann–Whitney test) are shown in Figure 5
suggesting that there is a positive correlation between
HLA-E expression and lower pT stage.
Correlation of HLA-E expression with Fuhrmann’s
grade of RCC (p = 0.0423, Kruskal-Wallis test) is shown
in Figure 6, and these findings suggest that there is a
positive correlation between HLA-E expression and bet-
ter Fuhrmann’s grade.
Discussion
Originally known as ‘sentinels of pregnancy’, non-
classical immuno-modulatory molecules HLA-G and
HLA-E were thought to be specifically expressed only
on the extravillous trophoblast. Their first described
function was to counter-attack maternal immune sur-
veillance and enable early tolerance and later acceptance
of semiallogeneic fetal graft by their immune-tolerogenic
properties.
The expression of these molecules by normal non-fetal
tissues was later described: HLA-G proteins have been
identified in thymic epithelial cells, in keratocytes from cor-
nea and in cells of erythropoietic lineage from the bone
marrow [6]. HLA-E antigen was described in B and T lym-
phocytes, natural killer cells, macrophages and megakaryo-
cytes; within the normal non-lymphoid organs, expressionFigure 1 Comparison of HLA-G expression levels in RCC tissue
and non-tumoral renal parenchyma (p = 0.0058, Mann–Whitney
test).is mainly restricted to endothelial cells [7]. However,
HLA-E mRNA transcripts were identified in almost all
human cells [8]. Under pathological neoplastic conditions,
the HLA-G protein was identified in a variety of human
malignancies.
As far as the prognostic significance of HLA-G under
neoplastic conditions is concerned, a body of literature
has emerged supporting the immune-tolerogenic role of
HLA-G based on worse prognosis of patients with HLA-
G positive tumors of different histotypes. Our results
confirmed already described [9] virtual down-regulation
of HLA-G expression in almost all samples of normal
kidney parenchyma and its up-regulation in RCC. Al-
though there is only one large study which specifically
analyzed possible prognostic significance of HLA-G up-
regulation in RCC [10] and that study does not indicate
negative prognostic influence of HLA-G expression, ourFigure 3 Relapse-free survival of RCC patients based on the
HLA-G expression (cut off = 75th percentile of HLA-G
expression levels in RCC tissue; p = 0,0401, Long-rank test).
Figure 4 Relapse-free survival of RCC patients based on the
HLA-E expression (cut off = 25th percentile of HLA-E expression
levels in RCC tissue; p = 0,0115, Long-rank test).
Figure 6 Correlation of HLA-E expression with Fuhrmann’s
grade of RCC (p = 0.0423, Kruskal-Wallis test).
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influencing relapse-free survival time. This observed
immuno-tolerogenic effect is in accordance with both
physiological functions of HLA-G and most reports that
evaluate the relationship of HLA-G tumoral positivity to
prognosis. Thus, aberrant HLA-G expression is found at
a relatively high frequency in RCC and might participate
in evasion of these tumor cells from immunosurveillance
by inhibiting lysis of RCC cells by immune effector cells.
Moreover, the aberrant activation of HLA-G expression
in RCC cell lines due to the influence of interferons was
described [9,11,12]. So, there is a tempting suggestion
that considering the immunotolerogenic function assigned
to date to HLA-G molecule, this induction effect of inter-
ferons could lessen or possibly even eliminate the effect of
immunotherapy (and to explain, at least in part, failure to
respond to immunotherapy).
Unlike HLA-G, the expression and function of HLA-E
in neoplastic processes remains poorly established andFigure 5 HLA-E expression levels in RCC of different pT stage
(p= 0.041, Mann–Whitney test).understood with contradictory literature reports. Most lit-
erature data indicate worse prognosis of patients with
HLA-E positive tumors of different histotypes.
[13-16] However, there are scarce reports which
counterintuitively (related to physiological immuno-
tolerogenic function of HLA-E in trophoblast) claim bet-
ter prognosis for patients with HLA-E positive tumors
[17-19]. We showed that HLA-E specific mRNA tran-
scripts are present in both normal and malignant kidney
tissue. Most importantly, our results also indicate posi-
tive influence to relapse-free survival in patients whose
RCC tissues show high concentrations of HLA-E specific
mRNA. Furthermore, there seems to be a positive cor-
relation between high concentrations of HLA-E specific
mRNA in neoplastic cells and better pT stage and lower
Fuhrmann’s grade of RCC. The explanation of these
counterintuitive effects of HLA-E in RCC could be the
direct engagement of the NKG2C activation receptors
instead of NKG2A inhibitory receptors [20]. Another
possibility is an antigen-specific recognition through the
T cells receptor expressed by NK-CTLs [18,21]. The last
possibility of activation is the competitive relief of
NKG2A-mediated inhibition upon HLA-E assembly with
peptides from donor proteins other than HLA class I
(for instance, heat peptides etc.): HLA-E molecules in
complex with these signal peptides are no longer recog-
nized by CD94/NKG2A inhibitory receptors. Such pep-
tide interference would gradually uncouple CD94/
NKG2A inhibitory recognition [22]. Thus, our results in-
dicate that the balance between activating and inhibitory
functions of multifunctional immuno-modulatory mol-
ecule HLA-E in RCC favors activation responses instead
of tolerogenic effects.
An aberrant activation of HLA-E expression in various
cell lines (other than RCC) due to the influence of inter-
ferons was also described [23-26]. Of note, one study
Figure 8 Positivity of RCC for the HLA-E, immunohistochemistry,
DAB method, clone MEM-E/02, Exbio Prague. Analysed by
Olympus BX45 microscope equipped with Olympus DP50 digital
camera. Olympus Viewfinder Lite™software was used to acquire and
process the image, 400×.
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(alpha vs. gamma) on effector cells: interferon-alpha sti-
mulates expression of stimulatory NKG2D receptors and
inhibits the expression of inhibitory NKG2A receptors
on NK cells whereas interpheron gamma increases the
expression of MICA and HLA-E cell surface proteins.
We speculate that interferon gamma therapy related in-
duction of HLA-E expression in RCC HLA-E negative
patients could be one of the mechanisms of efficient
interferon therapy.
As far as methodology is concerned, it would be also
possible to study these molecules in formalin-fixed par-
affin embedded material (Figure 7 and Figure 8). That
approach would have, though, three possible pitfalls: the
first are possible cross-reactions of used antibodies
[28,29] the second is the necessity of a subjective and
possibly an inaccurate semi-quantitative evaluation of
immunohistochemical slides and the third is possible re-
gional expressional variability. Our approach eliminates
all three possible pitfalls.
To summarize, for the first time, we described nega-
tive prognostic significance of HLA-G transcripts but
positive prognostic significance of HLA-E transcripts in
RCC. Thus, these molecules could represent useful prog-
nostic biomarkers in RCC. Further, we described for the
first time positive influence of HLA-E transcripts to bet-
ter pT stage and to higher nuclear Fuhrmann’s grade. In
our study, we also confirmed the absence of HLA-G spe-
cific mRNA and the presence of HLA-E specific mRNA
in normal renal parenchyma. Further work is required to
investigate these mechanisms in the context of
activation-inhibition responses of tumor immunosurveil-
lance. Characterization of HLA-G and HLA-E statusFigure 7 Positivity of RCC for the HLA-G, immunohistochemistry,
DAB method, clone MEM-G/1, Exbio Prague. Analysed by Olympus
BX45 microscope equipped with Olympus DP50 digital camera.
Olympus Viewfinder Lite™software was used to acquire and process
the image, 400×.could thus contribute to better prediction and monitor-
ing of RCC.
Conclusions
The role of immuno-modulatory nonclassical molecules
HLA-G and HLA-E in the development and in the clin-
ical course of RCC is still not well characterized.
Here, we described that HLA-G is downregulated in
normal kidney tissue; if it is up-regulated in RCC, then
it carries the worse prognosis. On the other hand, HLA-
E mRNA transcripts were present in both normal kidney
tissue and RCC and their increasing concentrations
counterintuitively carried better prognosis, more favor-
able pT stage and lower nuclear Fuhrmann’s grade.
These molecules could represent useful prognostic bio-
markers in RCC. Moreover, considering the fact that
there is known aberrant activation of HLA-G and HLA-
E expression by interferons, then identification of HLA-
G and HLA-E status could have an impact on the design
of T and NK cell-based immunotherapies in this disease
and contribute to better selection of RCC patients who
could possibly benefit from more tailored neoadjuvant
biological/immunological therapy.
The expression of both these molecules and their roles
in RCC deserve further study.
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